


**Product Name** : Atogepant  
**Cat. No.** : PC-60031  
**CAS No.** : 1374248-81-3  
**Molecular Formula** : C<sub>29</sub>H<sub>23</sub>F<sub>6</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 603.525  
**Target** : CGRP Receptor  
**Solubility** : 10 mM in DMSO

1. Rubio-Beltran E, et al. *Cephalalgia*. 2020 Apr;40(4):357-366.



## Biological Activity

Atogepant (MK-8031) is a potent and selective calcitonin gene-related peptide (**CGRP**) receptor antagonist with Ki of 2 pM (hCGRP).

Atogepant shows similar affinity for rhesus CGRP receptors (Ki = 0.009 nM), but a weaker affinity for rat and dog CGRP receptors (Ki = 0.7 nM and Ki = 1.2 nM, respectively).

Atogepant inhibited [<sup>125</sup>I]-amylin binding on membranes from cells expressing human recombinant AMY1 (Ki=1.8 nM).

Atogepant inhibited AMY-induced cAMP accumulation with an IC<sub>50</sub> of 2.4 nM on the AMY1 receptor, and an IC<sub>50</sub> of 1418 nM on the AMY3 receptor.

Atogepant exhibited significant affinity for the amylin1 receptor but lacked appreciable affinities for adrenomedullin, calcitonin and other known neurotransmitter receptor targets.

Atogepant dose-dependently inhibited facial allodynia in the rat nitroglycerine model and produced significant CIDV inhibition in primates.

## References

